Cargando…

Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents

Cancer surgery remains the primary treatment option for most solid tumors and can be curative if all malignant cells are removed. Surgeons have historically relied on visual and tactile cues to maximize tumor resection, but clinical data suggest that relapse occurs partially due to incomplete cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez Vargas, Servando, Lin, Christie, Tran Cao, Hop S., Ikoma, Naruhiko, AghaAmiri, Solmaz, Ghosh, Sukhen C., Uselmann, Adam J., Azhdarinia, Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279813/
https://www.ncbi.nlm.nih.gov/pubmed/34277418
http://dx.doi.org/10.3389/fonc.2021.674083
_version_ 1783722520744034304
author Hernandez Vargas, Servando
Lin, Christie
Tran Cao, Hop S.
Ikoma, Naruhiko
AghaAmiri, Solmaz
Ghosh, Sukhen C.
Uselmann, Adam J.
Azhdarinia, Ali
author_facet Hernandez Vargas, Servando
Lin, Christie
Tran Cao, Hop S.
Ikoma, Naruhiko
AghaAmiri, Solmaz
Ghosh, Sukhen C.
Uselmann, Adam J.
Azhdarinia, Ali
author_sort Hernandez Vargas, Servando
collection PubMed
description Cancer surgery remains the primary treatment option for most solid tumors and can be curative if all malignant cells are removed. Surgeons have historically relied on visual and tactile cues to maximize tumor resection, but clinical data suggest that relapse occurs partially due to incomplete cancer removal. As a result, the introduction of technologies that enhance the ability to visualize tumors in the operating room represents a pressing need. Such technologies have the potential to revolutionize the surgical standard-of-care by enabling real-time detection of surgical margins, subclinical residual disease, lymph node metastases and synchronous/metachronous tumors. Fluorescence-guided surgery (FGS) in the near-infrared (NIRF) spectrum has shown tremendous promise as an intraoperative imaging modality. An increasing number of clinical studies have demonstrated that tumor-selective FGS agents can improve the predictive value of fluorescence over non-targeted dyes. Whereas NIRF-labeled macromolecules (i.e., antibodies) spearheaded the widespread clinical translation of tumor-selective FGS drugs, peptides and small-molecules are emerging as valuable alternatives. Here, we first review the state-of-the-art of promising low molecular weight agents that are in clinical development for FGS; we then discuss the significance, application and constraints of emerging tumor-selective FGS technologies.
format Online
Article
Text
id pubmed-8279813
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82798132021-07-15 Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents Hernandez Vargas, Servando Lin, Christie Tran Cao, Hop S. Ikoma, Naruhiko AghaAmiri, Solmaz Ghosh, Sukhen C. Uselmann, Adam J. Azhdarinia, Ali Front Oncol Oncology Cancer surgery remains the primary treatment option for most solid tumors and can be curative if all malignant cells are removed. Surgeons have historically relied on visual and tactile cues to maximize tumor resection, but clinical data suggest that relapse occurs partially due to incomplete cancer removal. As a result, the introduction of technologies that enhance the ability to visualize tumors in the operating room represents a pressing need. Such technologies have the potential to revolutionize the surgical standard-of-care by enabling real-time detection of surgical margins, subclinical residual disease, lymph node metastases and synchronous/metachronous tumors. Fluorescence-guided surgery (FGS) in the near-infrared (NIRF) spectrum has shown tremendous promise as an intraoperative imaging modality. An increasing number of clinical studies have demonstrated that tumor-selective FGS agents can improve the predictive value of fluorescence over non-targeted dyes. Whereas NIRF-labeled macromolecules (i.e., antibodies) spearheaded the widespread clinical translation of tumor-selective FGS drugs, peptides and small-molecules are emerging as valuable alternatives. Here, we first review the state-of-the-art of promising low molecular weight agents that are in clinical development for FGS; we then discuss the significance, application and constraints of emerging tumor-selective FGS technologies. Frontiers Media S.A. 2021-06-30 /pmc/articles/PMC8279813/ /pubmed/34277418 http://dx.doi.org/10.3389/fonc.2021.674083 Text en Copyright © 2021 Hernandez Vargas, Lin, Tran Cao, Ikoma, AghaAmiri, Ghosh, Uselmann and Azhdarinia https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Hernandez Vargas, Servando
Lin, Christie
Tran Cao, Hop S.
Ikoma, Naruhiko
AghaAmiri, Solmaz
Ghosh, Sukhen C.
Uselmann, Adam J.
Azhdarinia, Ali
Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents
title Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents
title_full Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents
title_fullStr Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents
title_full_unstemmed Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents
title_short Receptor-Targeted Fluorescence-Guided Surgery With Low Molecular Weight Agents
title_sort receptor-targeted fluorescence-guided surgery with low molecular weight agents
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279813/
https://www.ncbi.nlm.nih.gov/pubmed/34277418
http://dx.doi.org/10.3389/fonc.2021.674083
work_keys_str_mv AT hernandezvargasservando receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents
AT linchristie receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents
AT trancaohops receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents
AT ikomanaruhiko receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents
AT aghaamirisolmaz receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents
AT ghoshsukhenc receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents
AT uselmannadamj receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents
AT azhdariniaali receptortargetedfluorescenceguidedsurgerywithlowmolecularweightagents